Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head

  • Authors:
    • Lin Wang
    • Deng-Ke Luo
    • Zhen-Yu Pan
  • View Affiliations

  • Published online on: March 28, 2013     https://doi.org/10.3892/mmr.2013.1401
  • Pages: 1482-1486
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the association between glucocorticoid receptors and steroid‑induced avascular necrosis of the femoral head (SANFH). Healthy New Zealand rabbits were randomly divided into 3 groups (n=16/group); the normal (no treatment), control (horse serum injections) and treatment (horse serum and methylprednisolone injections) groups. Methylprednisolone and horse serum injections were used to establish a SANFH model in rabbits; magnetic resonance imaging (MRI) and histopathological analysis were used to evaluate the SANFH rabbit model. Total cholesterol and triglyceride contents in the blood of SANFH rabbits were determined. The protein expression levels of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and type 2 (11β-HSD2) were determined using western blotting. The total cholesterol and triglyceride levels in the blood of methylprednisolone‑treated rabbits were significantly increased compared with the control and normal groups, which provides evidence in support of the metabolic disorder theory. Based on the results obtained from western blotting, the expression levels of 11β-HSD1 protein were increased, whereas the expression levels of 11β-HSD2 protein were decreased following injection. The results of the present study indicate that 11β-HSDs are important in the development of SANFH. Furthermore, 11β-HSDs may be important targets for preventing the development of ANFH in patients treated with steroids, which has a significant reference value for the use of steroids in clinical practice.

Introduction

Steroid-induced avascular necrosis of the femoral head (SANFH), frequently encountered in clinical practice, is a progressive pathological process. It occurs due to obstruction of the blood circulation in the femoral head induced by the improper use of hormones. Additionally, SANFH is able to induce in situ avascular necrosis and disability in a high proportion of patients. When no treatment is provided to patients, the femoral heads may deform or even collapse, impairing hip joint function and causing permanent disability (1). Currently, the incidence of SANFH is markedly increasing and has the potential to become the leading cause of ANFH. Numerous theories have been suggested in an attempt to explain the development of SANFH, including fat embolism (2,3), intravascular coagulation (3,4), intrafemoral head pressure change (5) and osteoporosis (6). However, the pathological mechanism of SANFH has not yet been fully elucidated (79). According to previous studies (1012), the lipometabolism disorder and intravascular coagulation theories may be used to explain the development of SANFH.

11β-hydroxysteroid dehydrogenases (11β-HSDs), including 11β-HSD type 1 (11β-HSD1) and type 2 (11β-HSD2), are the key metabolic enzymes for catalyzing the interconversion of active glucocorticoids (cortisol and corticosterone) and inert 11-keto forms (cortisone and 11-dehydrocorticosterone) (13). To date, numerous studies have demonstrated that 11β-HSD1 and 11β-HSD2 affect fat cell and endotheliocyte function (1417). During fat cell and endotheliocyte dysfunction, an abnormal blood flow in terminal vessels is induced and causes complications, including intravascular coagulation, microcirculation disturbance and vascular embolization, which may lead to femoral head necrosis (17). Therefore, the expression of 11β-HSD1 and 11β-HSD2 may be important in SANFH development.

To the best of our knowledge, no previous studies have investigated the association between 11β-HSD and SANFH. Results of the present study revealed the correlation between 11β-HSD and SANFH, via the determination of 11β-HSD1 and 11β-HSD2 expression in a rabbit model; this may have a significant reference value for the use of steroids in clinical practice.

Materials and methods

Animals

Healthy adult New Zealand rabbits (weight, 2.6–3.2 kg) were obtained from the Experimental Animal Center of Zhongnan Hospital of Wuhan University (Wuhan, China). All the experimental protocols used in this study were approved by the Animal Care and Use Committee of our Hospital.

Preparation of the SANFH rabbit model and sample collection

The SANFH rabbit model was prepared according to previously described methods (1,18), with minor modifications. Briefly, 48 healthy New Zealand rabbits were randomly divided into 3 groups (n=16/group); the normal (no treatment), control (vehicle only) and treatment groups (SANFH model). Rabbits of the control and treatment groups were injected with horse serum (10 ml/kg; HyClone Laboratories, Inc., Logan, UT, USA) through an ear vein. After 2 weeks, 6 ml/kg horse serum was similarly injected once a day for 2 days, followed by an injection of 20 mg/kg methylprednisolone (Pharmacia and Upjohn Company, Puurs, Belgium) into the abdomen of rabbits in the treatment group twice a week for 2 weeks. Following the methylprednisolone injection, 200,000 units of penicillin was injected into the buttock of each rabbit. In the normal and control groups, an equal amount of saline was injected into the buttock muscle. Three animals from each group were examined using magnetic resonance imaging (MRI) and histopathological analysis 2 weeks after the hormone injection. Additionally, the blood and femur head samples of 3 animals from each group were collected 0 (prior to hormone injection), 2, 4 and 8 weeks after the hormone injection.

MRI

An orthogonal head coil was placed on the anesthetized rabbit, with its center located on the hip joint, and the fast spin echo (SE) was used. T2-weighted imaging (T2WI; TR/TE, 2500/74 ms), T1-weighted imaging (T1WI; TR/TE, 420/20 ms) and T2WI fat-suppression sequence (FS-T2WI) were performed twice at the coronal position.

Histopathological analysis

Following the sacrifice of each rabbit, both femoral heads, including the metaphyses and thigh-bones, were removed. The tissue sections were dissected and fixed in 10% formalin, embedded in paraffin, cut into 5-μm-thick sections, de-paraffinized, rehydrated using standard techniques and stained using hematoxylin and eosin (H&E). The histopathological changes were evaluated using a microscope (Olympus, Tokyo, Japan).

Determination of total cholesterol and triglyceride contents

The automatic biochemistry analyzer (Advia 1650; Siemens Medical Solutions, Erlangen, Germany) was used to determine the total cholesterol and triglyceride contents in the blood samples of SANFH rabbits.

Western blotting

Total proteins of the femoral head tissue were extracted and equal amounts of proteins (75 μg) were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted on polyvinylidene difluoride (PVDF) membranes. These were probed with anti-HSDB1 and anti-HSDB2 rabbit polyclonal IgG (Wuhan Boster Bio-Engineering Co., Ltd., Wuhan, China) and subsequently with goat anti-rabbit/HRP IgG (Wuhan Boster Bio-Engineering Co., Ltd.), and detected using chemiluminescence. To determine the protein loading, antibodies against β-actin were used.

Statistical analysis

All the experiments were conducted in triplicate (at least) and the data are presented as the mean ± standard deviation (SD). The data were evaluated using one-way ANOVA, followed by Dunnett’s multiple comparisons test between different groups. The statistical significance of differences was analyzed using SPSS software (SPSS for Windows 15.0; SPSS Inc., Chicago, IL, USA) and P<0.05 was considered to indicate a statistically significant difference.

Results

MRI examination

The femoral heads of rabbits in the normal and control groups were symmetrical. In FS-T2WI, low fat level signals were observed in the cortex of the femoral head in the normal and control groups. By contrast, MRI in the treatment group revealed a larger articular cavity of the femoral head in rabbits of the treatment group. The high-level FS-T2WI signal at the metaphyses indicated that edema was present in the bone marrow in the treatment group (Fig. 1).

Histopathological observations

As shown in Fig. 2, changes in the periosteum, cartilage, trabeculae and hematopoietic organization were observed. The periosteum of the femoral heads in the control and normal groups were smooth, and cartilage cells were arranged in an organized manner. The trabeculae were intact and their arrangement was regular, compact and full. The bone cells in the trabeculae were clearly visible with few empty bone lacunae. There were abundant medullary hematopoietic and small fat cells with a normal morphology. By contrast, the periosteum of the femoral heads in the treatment group was incomplete with partially shed cartilage cells. There were a few thin trabeculae with a disordered texture and a number of trabeculae were broken into fragments. A few spindle-shaped osteoblasts were distributed along the trabeculae. The medullary hematopoietic areas were poorly organized, with fewer cells, a sparse capillary network and partially obstructed blood vessels (Fig. 2).

Levels of total cholesterol and triglycerides in the blood of SANFH rabbits

The total cholesterol and triglyceride levels in the blood of rabbits in the treatment group were significantly higher compared with those of the control and normal groups (P<0.01; Fig. 3). Furthermore, the total cholesterol and triglyceride levels in the blood of rabbits in the treatment group gradually increased following injection until the end of the observation period.

Western blotting

The expression levels of 11β-HSD1 and 11β-HSD2 proteins were determined using western blotting (Fig. 4). The expression levels of 11β-HSD1 and 11β-HSD2 proteins in the control and normal groups maintained a stable level. By contrast, the expression levels of 11β-HSD1 protein in the treatment group increased 2 weeks after the injection, whereas the expression levels of 11β-HSD2 protein in the treatment group decreased 2 weeks after the injection. Additionally, the expression levels of 11β-HSD1 protein in the treatment group were significantly higher compared with those of the control and normal groups at each time-point after the injection (P<0.001). However, the expression levels of 11β-HSD2 protein in the treatment group were significantly lower compared with those of the control and normal groups at each time point after the injection (P<0.001). The relative protein level was normalized to the intensity of β-actin, as determined by western blotting.

Discussion

Steroids have been used in clinical practice to inhibit inflammation, allergy and immune responses in numerous diseases. In 2003, steroids were widely used to treat severe acute respiratory syndrome (19). However, serious adverse reactions may be induced by steroid use, with SANFH being one of the most common. According to the results of previous studies, an increasing number of ANFH cases caused by steriod use have been reported and SANFH often occurs at an age of 30–50 years. Without treatment, hip joint dysfunction occurs in SANFH patients and this disease is considered to be an irreversible process (20,21). Numerous therapeutic methods have previously been used to treat SANFH, including hip arthroplasty, prosthesis and reconstructive surgery of the femoral head, in addition to treatments without surgery; however, these treatments were not particularly effective (2224). Furthermore, the pathogenesis of SANFH remains unclear. Thus, investigation into the pathogenesis of SANFH and novel therapeutic strategies is urgently required.

In the present study, a rabbit model of SANFH was established to explore potential molecular mechanisms underlying SANFH development. MRI and histopathological analyses were used to evaluate the SANFH rabbit model and these determined that the model had been successfully established and was able to be used for further investigation in this study.

Metabolic disorder has been hypothesized to be the mechanism that underlies SANFH development. Following high hormone intake, the serum concentration levels of lipids, including total cholesterol and triglycerides, are increased, leading to hyperlipidemia. This may cause fat embolism to be induced in the peripheral vessels, leading to intravascular coagulation (3,7,25). Subsequently, fibrin platelets are formed and thrombopoiesis occurs, which induces osteonecrosis via microcirculation disturbance in the femoral head (2628). Results of the present study demonstrated that the total cholesterol and triglyceride levels in the blood of rabbits treated with methylprednisolone were significantly increased compared with those of the control and normal groups; these results provide evidence in support of the metabolic disorder theory.

According to the results of previous studies, glucocorticoids are able to affect fat metabolism and endotheliocyte function, and may be associated with the necrosis of the femoral head (17). Additionally, glucocorticoids cause serious intramedullary fatty infiltration and induce a diminished blood flow. Complications, including intravascular coagulation, microcirculation disturbance and vascular embolization, are induced by fat cell and endotheliocyte dysfunction, which subsequently lead to ANFH. 11β-HSD1 and 11β-HSD2 are the two key enzymes that catalyze the conversion of inert 11-keto forms (cortisone) to active cortisol, or vice versa, thus regulating the access of glucocorticoids to steroid receptors (13). Results of the present study showed that the expression levels of 11β-HSD1 protein were increased, while the expression levels of 11β-HSD2 protein were decreased following injection. Therefore, these results indicate that 11β-HSDs are important in the development of SANFH and that 11β-HSDs are potentially important targets for preventing the development of ANFH in steroid-treated patients.

References

1 

Wen Q, Ma L, Chen YP, Yang L, Luo W and Wang XN: A rabbit model of hormone-induced early avascular necrosis of the femoral head. Biomed Environ Sci. 21:398–403. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Jones JP Jr: Intravascular coagulation and osteonecrosis. Clin Orthop Relat Res. 277:41–53. 1992.PubMed/NCBI

3 

Kawai K, Tamaki A and Hirohata K: Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J Bone Joint Surg Am. 67:755–763. 1985.PubMed/NCBI

4 

Nishimura T, Matsumoto T, Nishino M and Tomita K: Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res. 334:37–42. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Wang GJ, Lennox DW, Reger SI, et al: Cortisone-induced intrafemoral head pressure change and its response to a drilling decompression method. Clin Orthop Relat Res. 159:274–278. 1981.PubMed/NCBI

6 

Arlet J: Nontraumatic avascular necrosis of the femoral head. Past, present, and future. Clin Orthop Relat Res. 277:12–21. 1992.PubMed/NCBI

7 

Jones JP Jr: Fat embolism and osteonecrosis. Orthop Clin North Am. 16:595–633. 1985.PubMed/NCBI

8 

Mont MA, Jones LC, Einhorn TA, Hungerford DS and Reddi AH: Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res. (Suppl 355): S314–S335. 1998.PubMed/NCBI

9 

Drescher W, Bünger MH, Weigert K, et al: Methylprednisolone enhances contraction of porcine femoral head epiphyseal arteries. Clin Orthop Relat Res. 423:112–117. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Drescher W, Schneider T, Becker C, Hobolth J, Rüther W, Hansen ES and Bünger C: Selective reduction of bone blood flow by short-term treatment with high-dose methylprednisolone: An experimental study in pigs. J Bone Joint Surg Br. 83:274–277. 2001. View Article : Google Scholar : PubMed/NCBI

11 

Feng Y, Yang SH, Xiao BJ, Xu WH, Ye SN, Xia T, Zheng D, Liu XZ and Liao YF: Decreased in the number and function of circulation endothelial progenitor cells in patients with avascular necrosis of the femoral head. Bone. 46:32–40. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Fujioka M, Kubo T, Nakamura F, Shibatani M, Ueshima K, Hamaguchi H, Inoue S, Sugano N, Sakai T, Torii Y, Hasegawa Y and Hirasawa Y: Initial changes of non-traumatic osteonecrosis of femoral head in fat suppression images: bone marrow edema was not found before the appearance of band patterns. Magn Reson Imaging. 19:985–991. 2001. View Article : Google Scholar : PubMed/NCBI

13 

Seckl JR and Walker BR: Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology. 142:1371–1376. 2001.PubMed/NCBI

14 

Nakano D and Nishiyama A: Programmed 11β-hydroxysteroid dehydrogenase type 2 reduction: a possible cause of adult-onset disease? J Hypertens. 29:201–203. 2011.

15 

Kaur K, Hardy R, Ahasan MM, et al: Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis. 69:1185–1190. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Kitajima M, Shigematsu M, Ogawa K, et al: Effects of glucocorticoid on adipocyte size in human bone marrow. Med Mol Morphol. 40:150–156. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Kerachian MA, Séguin C and Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 114:121–128. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Matsui M, Saito S, Ohzono K, et al: Experimental steroid-induced osteonecrosis in adult rabbits with hypersensivity vasculitis. Clin Orthop Relat Res. 277:61–72. 1992.PubMed/NCBI

19 

Shi B, Li G, Wang P, Yin W, Sun G, Wu Q and Yu G: Effect of antler extract on corticosteroid-induced avascular necrosis of the femoral head in rats. J Ethnopharmacol. 127:124–129. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Jones LC and Hungerford DS: Osteonecrosis: etiology, diagnosis, and treatment. Curr Opin Rheumatol. 16:443–449. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Hungerford DS: Treatment of osteonecrosis of the femoral head: everything’s new. J Arthroplasty. 22(Suppl 1): 91–94. 2007.

22 

Beris AE, Payatakes AH, Kostopoulos VK, et al: Non-union of femoral neck fractures with osteonecrosis of the femoral head: treatment with combined free vascularized fibular grafting and subtrochanteric valgus osteotomy. Orthop Clin North Am. 35:335–343. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Nelson CL, Garrison RL, Walz BH and McLaren SG: Resurfacing of only the femoral head - treatment for young patients with osteonecrosis of the femoral head with collapse, delamination and significant head involvement. J Ark Med Soc. 100:162–163. 2003.PubMed/NCBI

24 

Asano T, Takahashi KA, Fujioka M, et al: ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics. 13:675–682. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Jones JP Jr and Sakovich L: Fat embolism of bone. A roentgenographic and histological investigation, with use of intra-arterial lipiodol, in rabbits. J Bone Joint Surg Am. 48:149–164. 1966.PubMed/NCBI

26 

Jones JP: Epidemiologlcal risk factors for non-traumatic osteonecrosis. Orthopade. 29:370–379. 2000.(In German).

27 

Ichiseki T, Matsumoto T, Nishino M, Kaneuji A and Katsuda S: Oxidative stress and vascular permeability in steroid-induced osteonecrosis model. J Orthop Sci. 9:509–5l. 5:2004.PubMed/NCBI

28 

Starklint H, Lausten GS and Arnoldi CC: Microvascular obstruction in avascular necrosis. Immunohistochemistry of l4 femoral heads. Acta Orthop Scand. 66:9–12. 1995. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2013
Volume 7 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Luo D and Pan Z: Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head. Mol Med Rep 7: 1482-1486, 2013
APA
Wang, L., Luo, D., & Pan, Z. (2013). Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head. Molecular Medicine Reports, 7, 1482-1486. https://doi.org/10.3892/mmr.2013.1401
MLA
Wang, L., Luo, D., Pan, Z."Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head". Molecular Medicine Reports 7.5 (2013): 1482-1486.
Chicago
Wang, L., Luo, D., Pan, Z."Expression of 11β-HSD in steroid-induced avascular necrosis of the femoral head". Molecular Medicine Reports 7, no. 5 (2013): 1482-1486. https://doi.org/10.3892/mmr.2013.1401